These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 22990266)
21. Companies throw their weight behind new antiobesity drugs. Cahoon L Nat Med; 2010 Feb; 16(2):136. PubMed ID: 20134442 [No Abstract] [Full Text] [Related]
22. Update on pharmacology of obesity: benefits and risks. Cabrerizo García L; Ramos-Leví A; Moreno Lopera C; Rubio Herrera MA Nutr Hosp; 2013 Sep; 28 Suppl 5():121-7. PubMed ID: 24010752 [TBL] [Abstract][Full Text] [Related]
23. Over-the-counter orlistat. A weight loss "Alli" or adversary on the horizon. Anderson T AWHONN Lifelines; 2006; 10(5):418-21. PubMed ID: 17069574 [No Abstract] [Full Text] [Related]
24. The FDA's risk/benefit calculus in the approvals of Qsymia and Belviq: treating an obesity epidemic while avoiding another fen-phen. Azebu LM Food Drug Law J; 2014; 69(1):87-111, ii-iii. PubMed ID: 24772687 [TBL] [Abstract][Full Text] [Related]
26. Diet drugs Belviq and Qsymia receive FDA approval: what dentists need to know. Wynn RL Gen Dent; 2013; 61(1):11-3. PubMed ID: 23302354 [No Abstract] [Full Text] [Related]
28. The fat of the matter. Nat Med; 2012 Aug; 18(8):1155. PubMed ID: 22869166 [No Abstract] [Full Text] [Related]
29. Market watch: upcoming market catalysts in Q3 2010. Hay M Nat Rev Drug Discov; 2010 Jul; 9(7):507. PubMed ID: 20592737 [No Abstract] [Full Text] [Related]
30. New obesity pill: new hopes, old fears. Lancet; 2010 Dec; 376(9758):2042. PubMed ID: 21168038 [No Abstract] [Full Text] [Related]
31. Panel advises against rimonabant approval. Traynor K Am J Health Syst Pharm; 2007 Jul; 64(14):1460-1. PubMed ID: 17617490 [No Abstract] [Full Text] [Related]
32. Is there a path for approval of an antiobesity drug: what did the Sibutramine Cardiovascular Outcomes Trial find? Downey M; Still C; Sharma AM Curr Opin Endocrinol Diabetes Obes; 2011 Oct; 18(5):321-7. PubMed ID: 21878755 [TBL] [Abstract][Full Text] [Related]
33. Employers, others not sold on new anti-obesity drugs. Reinke T Manag Care; 2012 Sep; 21(9):33-6. PubMed ID: 23050423 [No Abstract] [Full Text] [Related]
34. Food and Drug Administration's Obesity Drug Guidance Document: a short history. Colman E Circulation; 2012 May; 125(17):2156-64. PubMed ID: 22547756 [No Abstract] [Full Text] [Related]
35. Pharmacological treatment of obesity in Europe: waiting for the arrival of the white blackbird. Rubio MA Endocrinol Nutr; 2014 Dec; 61(10):501-4. PubMed ID: 25434595 [No Abstract] [Full Text] [Related]
36. Drug treatment of obesity. Bray GA; Ryan DH Psychiatr Clin North Am; 2011 Dec; 34(4):871-80. PubMed ID: 22098810 [TBL] [Abstract][Full Text] [Related]
37. Phentermine/topiramate for weight reduction and treatment of adverse metabolic consequences in obesity. Bays HE; Gadde KM Drugs Today (Barc); 2011 Dec; 47(12):903-14. PubMed ID: 22348915 [TBL] [Abstract][Full Text] [Related]
38. Orlistat: current status in clinical therapeutics. McClendon KS; Riche DM; Uwaifo GI Expert Opin Drug Saf; 2009 Nov; 8(6):727-44. PubMed ID: 19998527 [TBL] [Abstract][Full Text] [Related]
39. FDA-Approved Anti-Obesity Drugs in the United States. Daneschvar HL; Aronson MD; Smetana GW Am J Med; 2016 Aug; 129(8):879.e1-6. PubMed ID: 26949003 [TBL] [Abstract][Full Text] [Related]
40. Updates on obesity pharmacotherapy. Velazquez A; Apovian CM Ann N Y Acad Sci; 2018 Jan; 1411(1):106-119. PubMed ID: 29377198 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]